These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 7556242)

  • 1. Development of resistance to imipenem among nosocomial isolates of Pseudomonas aeruginosa.
    Başustaoğlu AC; Gün H; Saraçli MA; Baysallar M; Haznedaroğlu T
    Eur J Clin Microbiol Infect Dis; 1995 May; 14(5):469-70. PubMed ID: 7556242
    [No Abstract]   [Full Text] [Related]  

  • 2. Meropenem and imipenem activity against Pseudomonas aeruginosa isolates from the MYSTIC Program.
    Turner PJ
    Diagn Microbiol Infect Dis; 2006 Nov; 56(3):341-4. PubMed ID: 17049798
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The impact of ertapenem use on the susceptibility of Pseudomonas aeruginosa to imipenem: a hospital case study.
    Lima AL; Oliveira PR; Paula AP; Dal-Paz K; Rossi F; Zumiotti AV
    Infect Control Hosp Epidemiol; 2009 May; 30(5):487-90. PubMed ID: 19335227
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Resistance to imipenem among selected gram-negative bacilli in the United States.
    Gaynes RP; Culver DH
    Infect Control Hosp Epidemiol; 1992 Jan; 13(1):10-4. PubMed ID: 1545108
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Emergence of different resistance mechanisms in Pseudomonas aeruginosa in a patient treated with imipenem.
    Miró E; Navarro F; March F; Sanchez F; Mirelis B
    Eur J Clin Microbiol Infect Dis; 1995 Aug; 14(8):731-2. PubMed ID: 8566000
    [No Abstract]   [Full Text] [Related]  

  • 6. Comparative Activity of Carbapenem Testing (COMPACT) study in Germany.
    Valenza G; Seifert H; Decker-Burgard S; Laeuffer J; Morrissey I; Mutters R;
    Int J Antimicrob Agents; 2012 Mar; 39(3):255-8. PubMed ID: 22230334
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Resistance to imipenem in Pseudomonas aeruginosa.
    King A; Shannon K; Phillips I
    J Antimicrob Chemother; 1995 Dec; 36(6):1037-41. PubMed ID: 8821603
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Imipenem-resistant Pseudomonas aeruginosa: risk factors for nosocomial infections.
    Onguru P; Erbay A; Bodur H; Baran G; Akinci E; Balaban N; Cevik MA
    J Korean Med Sci; 2008 Dec; 23(6):982-7. PubMed ID: 19119440
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antibiotic resistance and molecular typing of Pseudomonas aeruginosa: focus on imipenem.
    de Freitas AL; Barth AL
    Braz J Infect Dis; 2002 Feb; 6(1):1-7. PubMed ID: 11980597
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In vitro antibacterial activity of rifampicin in combination with imipenem, meropenem and doripenem against multidrug-resistant clinical isolates of Pseudomonas aeruginosa.
    Hu YF; Liu CP; Wang NY; Shih SC
    BMC Infect Dis; 2016 Aug; 16(1):444. PubMed ID: 27553962
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Risk factors and clinical significance of bacteremia caused by Pseudomonas aeruginosa resistant only to carbapenems.
    Lee CH; Su TY; Ye JJ; Hsu PC; Kuo AJ; Chia JH; Lee MH
    J Microbiol Immunol Infect; 2017 Oct; 50(5):677-683. PubMed ID: 26188977
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Risk factors and clinical outcomes of nosocomial multi-drug resistant Pseudomonas aeruginosa infections.
    Cao B; Wang H; Sun H; Zhu Y; Chen M
    J Hosp Infect; 2004 Jun; 57(2):112-8. PubMed ID: 15183240
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In vitro activity of ceftazidime, cefepime and imipenem on 1,005 Pseudomonas aeruginosa clinical isolates either susceptible or resistant to beta-lactams.
    Bonfiglio G; Marchetti F
    Chemotherapy; 2000; 46(4):229-34. PubMed ID: 10859428
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Carbapenem-hydrolysing beta-lactamase from clinical isolates of Pseudomonas aeruginosa in Portugal.
    Cardoso O; Sousa JC; Leitão R; Peixe L
    J Antimicrob Chemother; 1999 Jul; 44(1):135. PubMed ID: 10459824
    [No Abstract]   [Full Text] [Related]  

  • 15. Activity of Ceftolozane-Tazobactam and Ceftazidime-Avibactam against Beta-Lactam-Resistant Pseudomonas aeruginosa Isolates.
    Humphries RM; Hindler JA; Wong-Beringer A; Miller SA
    Antimicrob Agents Chemother; 2017 Dec; 61(12):. PubMed ID: 28993338
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical impact of imipenem-resistant Pseudomonas aeruginosa bloodstream infections.
    Suárez C; Peña C; Tubau F; Gavaldà L; Manzur A; Dominguez MA; Pujol M; Gudiol F; Ariza J
    J Infect; 2009 Apr; 58(4):285-90. PubMed ID: 19297028
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Consumption of imipenem correlates with beta-lactam resistance in Pseudomonas aeruginosa.
    Lepper PM; Grusa E; Reichl H; Högel J; Trautmann M
    Antimicrob Agents Chemother; 2002 Sep; 46(9):2920-5. PubMed ID: 12183248
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Failure of quality control measures to prevent reporting of false resistance to imipenem, resulting in a pseudo-outbreak of imipenem-resistant Pseudomonas aeruginosa.
    Carmeli Y; Eichelberger K; Soja D; Dakos J; Venkataraman L; DeGirolami P; Samore M
    J Clin Microbiol; 1998 Feb; 36(2):595-7. PubMed ID: 9466787
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Nosocomial infectious potency of imipenem-resistant Pseudomonas aeruginosa isolated from obstetric and gynecologic infections.
    Yin XH; Mikamo H; Tamaya T
    J Infect Chemother; 2003 Mar; 9(1):97-100. PubMed ID: 12673417
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Selection of resistant variants by broad spectrum beta-lactam antibiotics: to what extent is there cross resistance between imipenem and other beta-lactam antibiotics?].
    Kahan F; Kropp H
    Immun Infekt; 1986 Nov; 14(6):232-5. PubMed ID: 3100429
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.